Related Experiment Video
Updated: May 25, 2026
07:35
Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice
Published on: January 26, 2024
Glucose sensor excludes hypoglycaemia as cause of death
Signe Schmidt1, Kirsten Nørgaard
1Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark. signe.schmidt@hvh.regionh.dk
Diabetes Research and Clinical Practice
|February 7, 2012
Summary
Determining the cause of death in unexpected Type 1 diabetes cases is challenging. Continuous glucose monitoring (CGM) data aided in verifying the cause of death in a patient on sensor-augmented pump therapy.
Area of Science:
- Endocrinology
- Forensic Pathology
- Medical Device Technology
Background:
- Unexpected deaths in Type 1 diabetes mellitus (T1DM) present diagnostic challenges.
- Accurate post-mortem verification of death cause is crucial for clinical and legal purposes.
- Sensor-augmented insulin pump therapy is increasingly used in T1DM management.
Observation:
- A 44-year-old male with T1DM on sensor-augmented pump therapy experienced an unexpected death.
- Continuous glucose monitoring (CGM) data was available from the patient's device.
- The patient's clinical history indicated T1DM management.
Findings:
- CGM data provided critical insights into the patient's glycemic status preceding death.
- Analysis of glucose trends and alerts from the CGM system assisted in determining the cause of death.
- The data helped to correlate glycemic excursions with potential fatal events.
Implications:
- CGM data can be a valuable tool in post-mortem investigations of unexpected deaths in T1DM patients.
- This case highlights the importance of preserving and analyzing device data in forensic contexts.
- Integrating CGM data into post-mortem diagnostics may improve accuracy and understanding of mortality in T1DM.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...